Mikkael Sekeres, MD details a clinical presentation of a 74-year-old man diagnosed 9 months ago with LR-MDS with a hemoglobin of 7.8 g/dL.
First in Class Telomerase Inhibitor (Imetelstat) for Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Dr Sekeres discusses when to start therapy for a patient who has lower-risk MDS with amnesia.
Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with imetelstat.
Dr Sekeres discusses treatment goals for a patient with lower-risk MDS.
Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with luspatercept.
Dr Sekeres discusses key takeaways for optimizing anemia management in lower-risk MDS, as well as where he sees the most significant unmet needs.
Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with lenalidomide.
Dr Sekeres shares his thoughts about the choice between an EMA and a telomerase inhibitor in the RS-negative patient.
Dr Sekeres discusses the adverse event profile and AE management of imetelstat.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
